AUS
NZ
UK
CA
USA
IND
Healthcare
Kalkine| ASX 200 Biotech Stock Recce Pharmaceuticals (ASX:RCE) Secures China Patent for Antibacterial Advancements
May 30, 2025 02:20 PM AEST| By Team Kalkine MediaHighlights,Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) receives patent grant in China for RECCE 327 and RECCE 529,Patent strengthens global protection covering use, administration, and manufacturing methods,Company progresses with trials across So...
Recce Pharmaceuticals’ China Patent Win Bolsters Antibacterial Strategy Amid Expanding ASX200 Opportunities
May 30, 2025 01:36 PM AEST| By Team Kalkine MediaHighlights,Recce secures China patent for RECCE 327 and RECCE 529,Phase III trials underway in Asia and planned in the US,Strategic move aligns with ASX200 index growth outlook,Recce Pharmaceuticals Ltd (ASX:RCE) has taken a significant step forward...
Kalkine: Prescient’s PTX-100 Enters Phase 2A Trial for Rare Lymphoma, Boosting ASX200 Biotech Momentum
May 30, 2025 01:31 PM AEST| By Team Kalkine MediaHighlights,Prescient begins Phase 2A trial of PTX-100 for rare lymphoma,Drug shows promising safety and response in earlier studies,Orphan and fast track FDA designations could speed development,Prescient Therapeutics (ASX:PTX) has officially commenc...
Imugene (ASX:IMU) Strengthens Clinical Leadership With New CMO Amid ASX200 Push
May 30, 2025 11:26 AM AEST| By Team Kalkine MediaHighlights,Imugene,names Dr John Byon as new Chief Medical Officer,Dr Byon brings vast experience in cancer immunotherapy,Clinical pipeline advancement aims to boost treatment options,Imugene Ltd (ASX:IMU), a clinical-stage immuno-oncology company, h...
Kalkine | Healius Limited (ASX:HLS) Slides Sharply Amid Revenue Concerns and Broader ASX 200 Movements
May 29, 2025 04:11 PM AEST| By Team Kalkine MediaHighlights,Healius Limited (ASX:HLS) declines amid ongoing revenue contraction and weak sentiment,Industry comparisons highlight pressure on valuation within the healthcare segment,ASX 200 benchmark shows mixed movements driven by varying sectoral pe...
Emyria’s (ASX:EMD) Breakthrough PTSD Results and ANU Partnership Highlight Innovation in Mental Health Care
May 29, 2025 03:55 PM AEST| By Team Kalkine MediaHighlights,63% of PTSD patients showed no further diagnosis criteria,Emyria partners with ANU to develop mental health care models,Strong positioning in innovative ASX300 healthcare space,Emyria (ASX:EMD), a clinical-stage biotech company, has shared...
Noxopharm's HERACLES Trial Receives Green Light, Boosting Momentum Within ASX300
May 29, 2025 03:42 PM AEST| By Team Kalkine MediaHighlights,HERACLES trial approved for SOF-SKN™ in Australia,Strategic focus on chronic inflammatory conditions,Operational setup begins with expert clinical team,Noxopharm Limited (ASX:NOX) has achieved a major milestone with the approval of its HER...
ASX 200 Healthcare Spotlight: RMD Shares Trade Below Historical Multiples
May 29, 2025 03:08 PM AEST| By Team Kalkine MediaHighlights,ResMed CDI (ASX:RMD) operates within the healthcare sector and maintains a dual listing on the ASX and NYSE,RMD shares reflect a lower price-to-sales ratio compared to historical averages, supported by revenue growth,The company provides C...
Invion’s INV043 Shows Promise in Skin Cancer Treatment as ASX200 Health Innovation Gains Momentum
May 29, 2025 02:51 PM AEST| By Team Kalkine MediaHighlights,INV043 shows no adverse events in Phase I/II NMSC trial,Treatment highlights diagnostic potential through fluorescence,Phase II to refine treatment strategy with adjusted dosage,Australian biotech company Invion (ASX:IVX) has shared encour...
EBOS Dips on Major Share Sale News – What It Means for the ASX200
May 29, 2025 02:40 PM AEST| By Team Kalkine MediaHighlights,EBOS shares fall after major shareholder divests stake,$881 million share block hits market sentiment,Stock remains part of ASX dividend stocks list,Shares of healthcare and pharmaceutical distributor,EBOS Group,(ASX:EBO) dropped sharply f...
Clarity Pharmaceuticals (ASX:CU6) Progresses AMPLIFY Trial with First Patient Imaging, Boosting Prospects in ASX200
May 29, 2025 12:29 PM AEST| By Team Kalkine MediaHighlights,Clarity Pharmaceuticals (CU6) advances phase three trial for prostate cancer diagnosis,First patient imaged in AMPLIFY trial soon after study launch,Potential breakthrough in early detection of recurrent prostate cancer,Shares of Clarity P...
Kalkine: Imugene (ASX:IMU) Schedules Key EGM to Decide on Share Consolidation and Capital Raise
May 27, 2025 03:22 PM AEST| By Team Kalkine MediaHighlights,Imugene (IMU) to host EGM on 26 June 2025,Shareholders to vote on consolidation and capital raising,Funds aimed at advancing key clinical programs,Imugene (ASX:IMU), a biotechnology company focused on innovative cancer immunotherapies, has...
Kalkine: Neuren Pharmaceuticals Delivers Strong Growth and Expansion Plans Amid ASX200 Momentum
May 27, 2025 03:13 PM AEST| By Team Kalkine MediaHighlights,Neuren posts A$166 million record income,DAYBUE drives global expansion outlook,Promising clinical trials support future pipeline,Neuren Pharmaceuticals (ASX:NEU) has made headlines with a remarkable financial performance for the year 2024...
Kalkine: PainChek Expands US Presence with Eldermark Partnership, Eyes Growth Ahead of ASX200 Inclusion
May 27, 2025 01:22 PM AEST| By Team Kalkine MediaHighlights,PainChek,teams up with,Eldermark,to grow US market reach,Integration to deliver AI-driven pain assessments in real-time,FDA clearance to unlock full-scale sales rollout,PainChek (ASX:PCK),has entered a strategic partnership with Eldermark...
Kalkine: Prescient Therapeutics (ASX:PTX) Advances Rare Blood Cancer Treatment with Phase 2a Trial Amid ASX200 Momentum
May 27, 2025 12:42 PM AEST| By Team Kalkine MediaHighlights:,Phase 2a study initiated for PTX-100 in rare Cutaneous T-Cell Lymphoma,Trial spans Australia, US, and Europe with up to 40 patients,PTX-100 targets unmet need in relapsed or refractory CTCL,Prescient Therapeutics (ASX:PTX) has reached a s...
ASX 200 Healthcare Giants: Performance Snapshot of CSL, SIG, PME, RMD, and FPH
May 26, 2025 05:26 PM AEST| By Team Kalkine MediaHighlights,CSL (ASX:CSL) shows modest gains while maintaining its leadership in biopharmaceuticals,SIG (ASX:SIG) continues to lead pharmacy distribution despite a slight decline,PME (ASX:PME) and RMD (ASX:RMD) experience minor pullbacks amid strong a...
Healthscope’s Future in the ASX300: No Taxpayer Bailout, Government Confirms
May 26, 2025 03:34 PM AEST| By Team Kalkine MediaHighlights,Government will not provide taxpayer bailout to Healthscope.,Patient care and hospital integrity remain top priorities.,Focus on orderly sale to protect all stakeholders.,The Australian Government has made it clear that Healthscope (ASX:HS...
ASX 200 Healthcare Shock: ASX:CBA Supports Healthscope Amid Receivership
May 26, 2025 02:49 PM AEST| By Team Kalkine MediaHighlights,Healthscope enters voluntary receivership amid severe financial strain and debt concerns,Commonwealth Bank of Australia (ASX:CBA) offers financial support to maintain hospital operations,Landlords issue breach notices as tenancy defaults e...
Recce Pharmaceuticals (ASX:RCE) Strengthens Patent Portfolio with Chinese Approval, Boosting Presence in ASX200 Pharma Sector
May 26, 2025 12:57 PM AEST| By Team Kalkine MediaHighlights,Recce secures patent approval in China for key anti-infective drug candidates.,Patent covers multiple bacterial and viral infections with varied administration methods.,Expansion enhances Recce’s global intellectual property footprint in m...
Which Healthcare Leader in the S&P/ASX Two Hundred and ASX All Ordinaries Tops Global Fund Holdings?
May 23, 2025 06:18 PM AEST| By Team Kalkine MediaWhich Healthcare Leader in the S&P/ASX Two Hundred and ASX All Ordinaries Tops Global Fund Holdings?
Advertise your brand on Kalkine Media